Back to Search
SCOTT ANTONIA, MD
MD
Medical Oncology Physician
NPI: 1669404091Individual
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
ME68757(FL)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
ME68757(FL)
Research & Publications (20)
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.
PMID 16467102·Clin Cancer Res·2006
3-trial
Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma.
PMID 11956426·J Urol·2002
3-trial
B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma.
PMID 10854153·World J Urol·2000
6-review
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
PMID 19139427·J Clin Oncol·2009
3-trial
Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer.
PMID 18827606·J Thorac Oncol·2008
3-trial
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
PMID 18824702·J Clin Oncol·2008
3-trial
Combined modality immunotherapy and chemotherapy: a new perspective.
PMID 18488219·Cancer Immunol Immunother·2008
6-review
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
PMID 18316570·Clin Cancer Res·2008
3-trial
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.
PMID 18300255·Cancer·2008
3-trial
Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
PMID 18157014·J Immunother·2008
3-trial
Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
PMID 17602079·J Clin Oncol·2007
3-trial
An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model.
PMID 17444959·Scand J Immunol·2007
8-other
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
PMID 17327609·J Clin Oncol·2007
3-trial
Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.
PMID 17326096·Cancer·2007
3-trial
A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
PMID 17103257·Ann Surg Oncol·2007
3-trial
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients.
PMID 16982775·Cancer Res·2006
3-trial
Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial.
PMID 16928835·Mol Cancer Ther·2006
3-trial
Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma.
PMID 16863838·J Pediatr Surg·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 12902 USF MAGNOLIA DR
TAMPA, FL 33612 - Phone
- (813) 745-4673
Quick Facts
- NPI
- 1669404091
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile